Fewer Than Half of U.S. Pharmacies Carry One of the Most Effective Drugs for Opioid Abuse

A pharmacist holding a box of medication.
June 13, 2022
Tara Law from Time writes about how few pharmacies carry buprenorphine, a life-saving drug to help treat opioid use disorder (OUD). Lucas Hill, Pharm.D., BCACP, director of the college's Pharmacy Addictions Research & Medicine (PhARM) program, offers his insight on the issue, and how the DEA's crackdown of the drug puts OUD patients at risk.

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

Immunologic Resilience: A New Metric to Accurately Gauge COVID-19’s Path

The COVID-19 virus.
September 8, 2021
UT Pharmacy and UT Health Science Center San Antonio Assistant Professor Grace C. Lee, Pharm.D., Ph.D. is the first author of a recently published study that unveiled a novel concept, “immunologic resilience,” to accurately predict which COVID-19 patients will advance to severe disease and which will not.

Vasquez Appears on BBC World Service to Discuss Z-DNA

DNA.
June 16, 2021
Division Head and Professor of Pharmacology and Toxicology Karen Vasquez, Ph.D. appeared on BBC World Service's Science in Action to talk about Z-DNA. Dr. Vasquez's research focuses on DNA damage and repair, genomic instability, gene targeting, DNA structure and cancer therapeutics.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

Kompella Receives Fulbright Award for Postdoctoral Research

A woman smiling.
March 16, 2021
Division of Pharmacology and Toxicology researcher Pallavi Kompella, Ph.D. has received a Fulbright U.S. Scholar Program award to research at the Biomedical Research Institute of Málaga in Spain.

Has a UT Professor Found a Way to Stop COVID-19 Vaccines From Spoiling?

A fruit roll treat floating in the clouds with a rainbow behind it and small viruses hovering around it.
February 24, 2021
Molecular Pharmaceutics and Drug Delivery Professor Maria A. Croyle, Ph.D. received extensive coverage in the March 2021 edition of Texas Monthly regarding her innovative peelable film drug delivery research. Among its many potential applications, Dr. Croyle’s technology could deliver COVID-19 vaccines through a small oral strip, without need for refrigeration or extensive storage and transportation infrastructure.

Croyle Earns Funding for SARS-CoV-2 Research

A woman smiling.
January 13, 2021
Molecular Pharmaceutics and Drug Delivery professor Maria A. Croyle R.Ph., Ph.D. earned 2021’s David Lehr Research Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Dr. Croyle will receive research funding to investigate novel regulatory mechanisms of drug metabolism in the context of active infection with SARS-CoV-2 and after recovery.

New Thin Film Technology to Revolutionize Storage and Distribution of Biologic Treatments and Vaccines

A hand touching a transparent sheet.
September 29, 2020
The newly-formed Jurata Thin Film will work to bring Dr. Maria Croyle's thin film technology to market, allowing biologics and vaccines to be packaged, shipped, and stored at room temperature for extended periods of time.

Croyle Lab Develops Innovative Vaccine Delivery Method

maria croyle vaccine 2020
March 4, 2020
Researchers in the lab of Dr. Maria Croyle have developed a peelable lightweight film that stabilizes biologics, is inexpensive, and withstands extreme temperature changes. The technology has already demonstrated proof of concept for model Ebola and H1N1 vaccines, and may prove an effective method of delivery for future treatments, such as for coronavirus that causes COVID-19.